Author

D. B. Lipka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2

Frequent Co-Authors

C. Plass· 3 shared J.-P. Mallm· 3 shared P. Lutsik· 3 shared J. A. Wierzbinska· 2 shared J. Hey· 2 shared K. Rippe· 2 shared M. D. Milsom· 2 shared S. Haas· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Plass

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

M. Hartmann, M. Schoenung, J. Rajak, V. Maurer, L. Hai, K. Bauer, M. Hakobyan, S. Staeble, J. Langstein, L. Jardine, R. Roelz, S. Bohler, E. Khabirova, A.-H. Maag, D. Vonficht, , D. B. Lipka

This study identifies oncofetal reprogramming in juvenile myelomonocytic leukemia, linking RAS-pathway activation to fetal gene expression and revealing CD52 as a therapeutic target.

bioRxiv · Oct 27, 2023Cancer Biology

Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13)

D. Weichenhan, A. Riedel, E. Sollier, U. H. Toprak, J. Hey, K. Breuer, J. A. Wierzbinska, A. Touzart, P. Lutsik, M. Baehr, A. Oestlund, C. Nilsson, S. Jacobsson, M. Edler, A. Waraky, , C. Plass

The paper shows MNX1 overexpression in t(7;12)(q36;p13) AML is due to enhancer hijacking, not oncofusion, and is common in pediatric cases.

bioRxiv · Sep 13, 2023 · PreprintCancer Biology

Loss of Usp22 enhances histone H2B monoubiquitination and stimulates intracellular and systemic interferon immunity

N. Dietlein, X. Wang, E. Rodriguez Correa, B. Erbil, D. B. Lipka, Y. Begus-Nahrmann, R. L. Kosinsky, S. A. Johnsen, T. H. Winkler, H.-R. Rodewald

The paper shows that loss of Usp22 increases H2Bub1 levels, leading to enhanced ISG expression and IFN immunity in mice.

bioRxiv · Apr 9, 2021 · PreprintImmunology

Hematopoietic stem cells fail to regenerate following inflammatory challenge.

R. Bogeska, P. Kaschutnig, M. Fawaz, A.-M. Mikecin, M. Buechler-Schaeff, S. Paffenholz, N. Asada, F. Frauhammer, F. Buettner, M. Ball, J. Knoch, S. Staeble, D. Walter, A. Petri, M. J. Carreno-Gonzalez, , M. D. Milsom

This study shows that repeated inflammatory challenges lead to progressive depletion of functional HSCs with no recovery, contributing to age-related hematopoietic decline.

bioRxiv · Aug 1, 2020Cell Biology

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL

J. A. Wierzbinska, R. Toth, N. Ishaque, K. Rippe, J.-P. Mallm, L. Klett, D. Mertens, T. Zenz, T. Hielscher, M. Seifert, R. Kueppers, Y. Assenov, P. Lutsik, S. Stilgenbauer, P. M. Roessner, , D. B. Lipka

This study introduces Methyl-COOM, a method to identify cell-of-origin and CLL-specific epigenetic aberrations by analyzing DNA methylation patterns.

bioRxiv · Feb 4, 2020Cancer Biology